MoonLake Immunotherapeutics (MLTX)
40.86
+0.17
(+0.42%)
USD |
NASDAQ |
May 16, 16:00
40.85
-0.01
(-0.02%)
After-Hours: 20:00
MoonLake Immunotherapeutics Free Cash Flow (Quarterly): -15.16M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -15.16M |
| December 31, 2023 | -12.34M |
| September 30, 2023 | -9.251M |
| June 30, 2023 | -12.16M |
| March 31, 2023 | -9.024M |
| Date | Value |
|---|---|
| December 31, 2022 | -11.60M |
| September 30, 2022 | -9.352M |
| June 30, 2022 | -20.76M |
| March 31, 2022 | -14.20M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-20.76M
Minimum
Jun 2022
-9.024M
Maximum
Mar 2023
-12.65M
Average
-12.16M
Median
Jun 2023
Free Cash Flow (Quarterly) Benchmarks
| Qiagen NV | 94.72M |
| LENZ Therapeutics Inc | -23.94M |
| AC Immune SA | 0.8868M |
| CRISPR Therapeutics AG | 109.03M |
| Addex Therapeutics Ltd | -0.5575M |